Northwest Bioth Cmn (NWBO): Price and Financial Metrics

Northwest Bioth Cmn (NWBO): $0.48

0.03 (-5.88%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

D

Add NWBO to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#215 of 362

in industry

NWBO Price/Volume Stats

Current price $0.48 52-week high $1.09
Prev. close $0.51 52-week low $0.40
Day low $0.48 Volume 1,678,100
Day high $0.52 Avg. volume 1,740,458
50-day MA $0.54 Dividend yield N/A
200-day MA $0.64 Market Cap 577.91M

NWBO Stock Price Chart Interactive Chart >


Northwest Bioth Cmn (NWBO) Company Bio


Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies. The company was founded in 1996 and is based in Bethesda, Maryland.


NWBO Latest News Stream


Event/Time News Detail
Loading, please wait...

NWBO Latest Social Stream


Loading social stream, please wait...

View Full NWBO Social Stream

Latest NWBO News From Around the Web

Below are the latest news stories about NORTHWEST BIOTHERAPEUTICS INC that investors may wish to consider to help them evaluate NWBO as an investment opportunity.

Northwest Biotherapeutics Announces That A Marketing Authorization Application Has Been Submitted To The UK MHRA For DCVax®-L For Glioblastoma

Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that a Marketing Authorization Application (MAA) was submitted yesterday to the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK for DCVax®-L for glioblastoma brain cancer.

Yahoo | December 21, 2023

Northwest Biotherapeutics Provides Update On Final Preparations For Marketing Authorization Application

Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, provided an update today about the final preparations for the Marketing Authorization Application (MAA) that will be submitted to the Medicines and Healthcare Products Regulatory Agency (MHRA)(the equivalent of the U.S. FDA) in the U.K. for commercial approval of the Company's DCVax®-L treatment for glioblastoma.

Yahoo | November 22, 2023

Northwest Biotherapeutics Provides Update On Near Term Plans For Submission of Marketing Authorization Application

Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, provided an update today about its progress toward submission of a Marketing Authorization Application (MAA) to the Medicines and Healthcare Products Regulatory Agency (MHRA)(the equivalent of the U.S. FDA) in the U.K. for commercial approval of the Company's DCVax®-L treatment for glioblastoma.

Yahoo | October 13, 2023

Northwest Biotherapeutics Announces That Dr. Linda Liau Has Joined The Company's Scientific Advisory Board

Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announces that Dr. Linda Liau, MD, PhD, MBA has joined the Company's Scientific Advisory Board (SAB).

Yahoo | September 12, 2023

Northwest Biotherapeutics Announces Completion of Prerequisites, and Plans for Submission of Marketing Authorization Application

Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announces that it plans to submit a Marketing Authorization Application (MAA) in the U.K., to the Medicines and Healthcare Products Regulatory Agency (MHRA)(the equivalent of the U.S. FDA), for commercial approval of the Company's DCVax®-L treatment for glioblastoma.

Yahoo | August 29, 2023

Read More 'NWBO' Stories Here

NWBO Price Returns

1-mo -1.07%
3-mo -21.16%
6-mo -28.89%
1-year -4.00%
3-year -65.47%
5-year 77.78%
YTD -31.53%
2023 -10.64%
2022 12.07%
2021 -54.10%
2020 609.63%
2019 4.57%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!